IX-01
Phase 2- Indications
- Premature ejaculation
Company intelligence / Profile preview
Ixchelsis
Sandwich, England, United Kingdomassets.publishing.service.gov.uk ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Phase 2
01
Overview
Ixchelsis has developed IX‑01, an oxytocin receptor antagonist for premature ejaculation. The drug has completed Phase 1 studies and demonstrated positive proof of concept in a study of patients with severe lifelong premature ejaculation. It is currently being evaluated in a Phase IIb dose-ranging study.
- Therapeutic areas
- Men's Health
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Chorus (Eli Lilly's early phase virtual drug development arm)TVM Life Science Ventures VIIPfizer Ventures
Beyond the preview
Go deeper on Ixchelsis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ixchelsis.